Several studies have shown that response to abiraterone following enzalutamide is limited23,24; however, the present case raises the possibility that, on rare occasions, enzalutamide may eradicate the clones with AR aberrations associated with abiraterone resistance and re-sensitize the tumor to abiraterone. The gene discussed is AR; the disease is neoplasm.